ReviewReproductive sciences (Thousand Oaks, Calif.)2012
Medical treatment of uterine leiomyoma.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters.BMC women's health · 2026Pooled it
- Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.BMC women's health · 2022Pooled it
- Selective progesterone receptor modulators (SPRMs) for uterine fibroids.The Cochrane database of systematic reviews · 2017Pooled it
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.The New England journal of medicine · 2021Trial
- Effect of anesthetic technique on serum vascular endothelial growth factor C and prostaglandin E2 levels in women undergoing surgery for uterine leiomyomas.The Journal of international medical research · 2020Trial
- Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.Obstetrics and gynecology · 2019Trial
- Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial.Obstetrics and gynecology · 2018Trial
- Autophagy modulation in gynaecologic oncology: insights into immune regulation and therapeutic potential.Frontiers in immunology · 2026Review
- Illuminating the Intricacies: A Comparative Cross-Sectional Sonographic Evaluation of Degenerative Changes in Leiomyomas Through Post-Processing Technique.Diagnostics (Basel, Switzerland) · 2025Article
- Cellulose Plant-Derived Scaffolds as a Tool for Myometrium Modeling.International journal of molecular sciences · 2025Article
- Management of Myomectomy Scar Pregnancy: A Scoping Review.Medicina (Kaunas, Lithuania) · 2025Article
- A giant degenerative uterine leiomyoma mimicking an ovarian neoplasm: Case report.SAGE open medical case reports · 2025Article
- Exploring the cost implications of different treatment modalities for uterine fibroids under the DRG system.Frontiers in public health · 2025Article
- Complex Presentation of Uterus Didelphys With Bilateral Leiomyomas: A Case Report.Case reports in obstetrics and gynecology · 2025Article
- Tailoring the Diagnostic Pathway for Medical and Surgical Treatment of Uterine Fibroids: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- How safe is high-intensity focused ultrasound? An intriguing solution for obstetric and gynecological diseases: A systematic review.Turkish journal of obstetrics and gynecology · 2024Article
- Abnormal Uterine Bleeding With Leiomyomas: A Case Report of Its Natural Course and Therapeutic Management.Cureus · 2024Article
- Disseminated Peritoneal Leiomyomatosis-A Challenging Diagnosis-Mimicking Malignancy Scoping Review of the Last 14 Years.Biomedicines · 2024Review
- A systematic review of the side effects of high-intensity focused ultrasound ablation of uterine fibroids.Proceedings (Baylor University. Medical Center) · 2024Review
- Optimization of Diagnosis-Related Groups for 14,246 Patients with Uterine Leiomyoma in a Single Center in Western China Using a Machine Learning Model.Risk management and healthcare policy · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Uterine leiomyomas (also called myomata or fibroids) are the most common gynecologic tumors in the United States. The prevalence of leiomyomas is at least 3 to 4 times higher among African American women than in white women. Pathologically, uterine leiomyomas are benign tumors that arise in any part of the uterus under the influence of local growth factors and sex hormones, such as estrogen and progesterone. These common tumors cause significant morbidity for women and they are considered to be the most common indication for hysterectomy in the world; they are also associated with a substantial economic impact on health care systems that amounts to approximately $2.2 billion/year in the United States alone. Uterine myomas cause several reproductive problems such as heavy or abnormal uterine bleeding, pelvic pressure, infertility, and several obstetrical complications including miscarriage and preterm labor. Surgery has traditionally been the gold standard for the treatment of uterine leiomyomas and has typically consisted of either hysterectomy or myomectomy. In recent years, a few clinical trials have evaluated the efficacy of orally administered medications for the management of leiomyoma-related symptoms. In the present review, we will discuss these promising medical treatments in further detail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.